Xiaolong Tang, Longzhou Chen, Amin Li, Shiyu Cai, Yinci Zhang, Xueke Liu, . . . Dong Ma. (2018). Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Taylor & Francis Group.
Chicago Style (17th ed.) CitationXiaolong Tang, et al. Anti-GPC3 Antibody-modified Sorafenib-loaded Nanoparticles Significantly Inhibited HepG2 Hepatocellular Carcinoma. Taylor & Francis Group, 2018.
MLA (9th ed.) CitationXiaolong Tang, et al. Anti-GPC3 Antibody-modified Sorafenib-loaded Nanoparticles Significantly Inhibited HepG2 Hepatocellular Carcinoma. Taylor & Francis Group, 2018.
Warning: These citations may not always be 100% accurate.